Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Klaus Wilthoner"'
Autor:
Jakob Michael Riedl, Florian Posch, Gerald Prager, Wolfgang Eisterer, Leopold Oehler, Thamer Sliwa, Klaus Wilthoner, Andreas Petzer, Petra Pichler, Eva Hubmann, Thomas Winder, Sonja Burgstaller, Markus Korger, Johannes Andel, Richard Greil, Hans-Joerg Neumann, Martin Pecherstorfer, Kathrin Philipp-Abbrederis, Angela Djanani, Birgit Gruenberger, Friedrich Laengle, Ewald Wöll, Armin Gerger
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: The pretreatment De Ritis ratio [aspartate transaminase (AST)/alanine transaminase (ALT)] has been shown to be an adverse prognostic marker in various cancer entities. However, its relevance to advanced pancreatic ductal adenocarcinoma (P
Externí odkaz:
https://doaj.org/article/6ae640a6f55e4ed2b9869593c943f051
Autor:
Gerald W. Prager, Andreas Schmiderer, Klaus Wilthoner, Angela Djanani, Matthias Unseld, Hossein Taghizadeh, Dieter Buchinger
Publikováno v:
Cancer Chemotherapy and Pharmacology
Background Therapeutic options are limited for advanced, metastatic biliary tract cancer. The pivotal NAPOLI-1 trial demonstrated the superior clinical benefit of nanoliposomal irinotecan (Nal-IRI) in gemcitabine-pretreated patients with metastatic p
Autor:
B. Mlineritsch, Catharina Arnold-Schrauf, Johannes Andel, Birgit Gruenberger, Klaus Wilthoner, Robert Trondl, Leopold Oehler, Hans-Joerg Neumann, Thomas Winder, Andreas L. Petzer, Kathrin Philipp-Abbrederis, Wolfgang Eisterer, Armin Gerger, Petra Pichler, Gerald W. Prager, Angela Djanani, Friedrich Laengle, Markus Korger, Martin Pecherstorfer, Sonja Heibl, Eva Hubmann, Ewald Wöll, Thamer Sliwa
Publikováno v:
European journal of cancer (Oxford, England : 1990). 143
Background Pancreatic cancer (PC) ranks among the deadliest malignancies worldwide. In the MPACT study, first-line nab-paclitaxel plus gemcitabine (nab-P/G) demonstrated activity (median overall survival [OS], 8.7 months) and tolerability in patients
Autor:
Leopold Oehler, Johannes Andel, Thamer Sliwa, Klaus Wilthoner, Eva Hubmann, Richard Greil, Petra Pichler, Thomas Winder, Ewald Wöll, Gerald W. Prager, Jakob M. Riedl, Andreas L. Petzer, Hans-Joerg Neumann, Markus Korger, Armin Gerger, Kathrin Philipp-Abbrederis, Wolfgang Eisterer, Martin Pecherstorfer, Friedrich Laengle, Florian Posch, Sonja Burgstaller, Angela Djanani, Birgit Gruenberger
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology
Background: The pretreatment De Ritis ratio [aspartate transaminase (AST)/alanine transaminase (ALT)] has been shown to be an adverse prognostic marker in various cancer entities. However, its relevance to advanced pancreatic ductal adenocarcinoma (P